Navigation Links
Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
Date:1/31/2008

Two clinical trials of the novel drug romiplostim (Nplate) show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura (ITP), a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital (MGH) investigator, in the February 2 issue of The Lancet.

Many ITP patients have had to choose between no therapy or a treatment with limited efficacy and potentially serious side effects, says David Kuter, MD, DrPhil, director of Clinical Hematology at MGH and lead author of the Lancet study. The low toxicity and high response to this drug may convert a potentially life-threatening condition to one that can be easily managed with a weekly injection.

ITP is a chronic disorder in which the immune system destroys platelets, blood cells that help prevent bleeding. While some ITP patients experience only increased bruising, others may have serious bleeding and occasionally dangerous hemorrhage. Recent investigations suggest that, in addition to the destruction of existing platelets, ITP also may be due to reduced platelet production. Currently available treatments for ITP including steroid drugs, which have significant side effects, and removal of the spleen (splenectomy) are designed to reduce platelet destruction and may be ineffective in many patients.

Thrombopoietin is the natural regulator of platelet production. Kuter was one of the original discoverers of the hormone in 1994 and has been active in developing thrombopoietic drugs ever since. Romiplostim is a unique peptibody a peptide antibody that stimulates platelet production by mimicking the action of thrombopoietin. Earlier Phase 1 and 2 trials have shown that romiplostim increases platelet production in healthy volunteers and in short-term treatment of ITP patients.

The double-blinded Phase 3 trials were conducted at 35 sites in the U.S. and Europe. One trial enrolled 63 splenectomized patients, the other included 62 patients who retained their spleens. Both groups were randomly assigned to receive either romiplostim or a placebo in weekly injections during the 24-week study period. Participants platelet levels were monitored during the trial, and dosage was adjusted to achieve a target platelet count of 50,000/ml.

Among the 42 splenectomized patients who received romiplostim, nearly 80 percent reached the target platelet count during at least four weeks of the study, and 38 percent achieved a durable response, maintaining a target platelet count during at least six of the last eight weeks of the study. In the non-splenectomized patients, 88 percent had at least four target platelet count measurements, with 61 percent achieving a durable response.

More than half the patients receiving romiplostim were able to discontinue all other ITP medications they were taking, and 35 percent reduced other therapies. While over half the participants in the placebo groups of both studies needed rescue medications to treat or prevent bleeding episodes, significantly fewer of those receiving the active medication needed such treatment.

Were seeing dramatic results for this totally new approach to treating people with ITP, Kuter says. Ive been working on the development of thrombopoietin since 1983, and its very gratifying to participate in its discovery, purification, drug development and now the studies showing its clinical effectiveness. He adds that his MGH team and other researchers are conducting other romiplostim trials and will continue to investigate the drugs usefulness for treating ITP and other conditions of reduced platelet production, such as those caused by cancer or cancer treatment.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery
2. A New Series Is Born on Discovery Health
3. ITRAC on track and bridging gap between academic research and applied discovery
4. Discovery opens door to personalized asthma therapy
5. Linguamatics and 81qd Sign Multi-Year Collaboration in Knowledge Discovery for Product Life Cycle Management
6. Fight against hay fever and other allergies helped by new immune system discovery
7. Discovery Healths Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle
8. Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health
9. Kaiser Permanente and Discovery Health Team Up to Fight Childhood Obesity Epidemic
10. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
11. OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... years, Doctors on Liens has published a directory of the top doctors working ... When the company started in 1997, the directory was a single page focusing on chiropractors ... directory features a vast array of medical specialists stretching from Sacramento to San ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and ... of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, ... will give parents and other caregivers the opportunity to share stories and advice, seek ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research ... labeling, storing, shipping and disposal. The new version is a faster and a ...
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary ... included in the Emergency Response Training and Support Services ... excited to have LifeVac become part of the ERTSS ... Founder and CEO of LifeVac. "Having an established network ... and effectively will help leverage our efforts to spread ...
(Date:12/2/2016)... -- PipelineRx, a leading medication management technology company focused ... its SaaS-based telepharmacy platform, PowerGridRx™ , at ... Clinical Meeting and Exhibition, December 5-7 in ... hospital clients nationally, the Company is a leader ... improve pharmacy operations, enhance patient safety, and reduce ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: